Navigation Links
ChemBridge Research Laboratories, Inc. (CRL) has Established an Industry Record and Benchmark in Hit-to-Lead Libraries Turn-around Time
Date:8/7/2008

SAN DIEGO, Aug. 7 /PRNewswire/ -- ChemBridge Research Laboratories, Inc. (CRL) announced today that it has established an industry record in turn-around time for hit-to-lead follow-up libraries. Such ultra-fast hit-to-lead libraries are now produced in CRL's San Diego facilities in a matter of three to six days which enables critical acceleration of our clients' medicinal chemistry projects and sets a new industry benchmark. This state-of-the-art high-throughput chemistry technology was developed at CRL over the last seven years and refined in collaborations with Pfizer, Merck, AstraZeneca and others.

CRL's ultra-fast library production process is optimized at every step and includes: on-the-fly building block validation and protocol adjustment; one to three parallel synthesis steps across a very broad reaction range; high-throughput HPLC purification and LC/MS analysis; data processing; and robotic reformatting to ready-to-be-shipped custom plates/vials. The expertise, problem solving ability, and versatility of synthetic skills of CRL's chemists (the majority of whom are PhD's) also allow for rapid development of new parallel synthetic protocols and multi-step synthesis of intermediates and templates on-the-fly for the most challenging research-intensive hit-to-lead libraries.

"We are very pleased that our CRL chemists have been able to achieve speed and efficiency in hit-to-lead library production which even a year ago was not considered possible," said Eugene Vaisberg, Chairman and CEO of ChemBridge Corporation and CRL. "Their ability to produce and deliver high quality hit-to-lead libraries in less than a week continues the ChemBridge tradition of setting a gold standard in discovery chemistry outsourcing. It also offers a substantial competitive advantage for our clients allowing their precious medicinal chemistry resources to focus on their core expertise and to improve their hit-to-drug candidate success rate and timelines. This is of foremost importance now when research efficiency and productivity becomes the 'name of the game' for the pharmaceutical and biotech industry."

About ChemBridge Research Laboratories, Inc. (CRL)

ChemBridge Research Laboratories, Inc. (CRL), http://www.chembridgeresearch.com, is a San Diego based discovery chemistry CRO, which provides chemistry solutions for early stages of small molecule drug discovery. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL has now become a center of excellence in high-throughput medicinal chemistry with a particular focus on ultra-fast hit-to-lead libraries. CRL's world-class research team has exceeded expectations in all its collaborations, including multi-year alliances with Pfizer, Merck, AstraZeneca and other major pharmaceutical and biotech companies.

About ChemBridge Corporation

ChemBridge Corporation, http://www.chembridge.com, is a leading global discovery chemistry CRO and screening compound library provider with an impeccable 15 year track record of quality and deliverability. ChemBridge is a San Diego based company which operates a state-of-the-art offshore discovery chemistry research site in Moscow, Russia. ChemBridge's CRO business includes multi-year strategic alliances with major pharmaceutical companies such as Pfizer, Merck, and AstraZeneca, as well as smaller research collaborations with mid-size pharmaceutical and biotech companies. Over 500 pharmaceutical and biotech companies and universities worldwide have also taken advantage of ChemBridge's portfolio of advanced discovery chemistry off-the-self products, including its library of 700,000 diverse drug-like small molecule screening compounds and 10,000 building blocks.


'/>"/>
SOURCE ChemBridge Research Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers report periodontal disease independently predicts new onset diabetes
2. Scripps research team unravels new cellular repair mechanism
3. Researchers Find Genes That Influence West Nile Virus
4. New Research From Best Practices: Pharmaceutical New Product Planning - Structure and Activities to Drive Growth and Profitability
5. UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research
6. Researchers unveil vital key to cancer
7. Researchers find differences in swallowing mechanism of Rett syndrome patients
8. Dartmouth researchers say too many children see extreme violence in movies
9. LegalView Brain Injury Site Reports Department of Veteran Affairs Request for Research on TBI and Soldiers
10. BCBSA: Time Is Right for Comparative Effectiveness Research Institute
11. Penn researchers find a new role for a Foxy Old Gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: